Outcomes in participants switching from FVIII replacement therapy to efanesoctocog alfa prophylaxis in XTEND-1: a post hoc analysis
Open Access
- 20 January 2026
- journal article
- Published by SAGE Publications in Therapeutic Advances in Hematology
- Vol. 17
Abstract
Background: Efanesoctocog alfa is a first-in-class high-sustained factor VIII (FVIII) replacement therapy. In the phase III XTEND-1 (NCT04161495) study, once-weekly efanesoctocog alfa prophylaxis (50 IU/kg) was well-tolerated and achieved high-sustained factor levels in the normal to near-normal range (>40%) for most of the week. Objective: To report outcomes in previously treated participants with severe haemophilia A aged ⩾12 years from an observational study who switched to efanesoctocog alfa prophylaxis during XTEND-1. Design: Paired assessment of participants from an observational study who enrolled in the phase III XTEND-1 study. Methods: Seventy-eight participants switched from marketed standard half-life (SHL) or extended half-life (EHL) FVIII prophylaxis to once-weekly efanesoctocog alfa prophylaxis (50 IU/kg). Endpoints included annualized bleed rates (ABRs), treatment of bleeding episodes, injection frequency and FVIII consumption. Results: Pre-study, 44 (56%) and 34 (44%) participants received SHL FVIII or EHL FVIII prophylaxis, respectively. In the overall population, a significant reduction in ABR from 2.96 to 0.69 ( p < 0.0001) was observed following the switch to efanesoctocog alfa prophylaxis as well as reductions in spontaneous, traumatic, joint and spontaneous joint ABRs ( p < 0.0001). Significant reductions in mean weekly injection frequency were observed, from 2.8 to 1.0 in the SHL FVIII cohort ( p < 0.0001) and from 1.8 to 1.0 in the EHL FVIII cohort ( p < 0.0001). Mean annualized factor consumption reduced by 47% in the SHL FVIII cohort and 30% in the EHL FVIII cohort. Conclusion: Collectively, the results of this post hoc analysis demonstrate the benefits of once-weekly efanesoctocog alfa prophylaxis over SHL or EHL FVIII prophylaxis on bleed rates, injection frequency and consumption. Trial registration: Observational study: 242HA201/OBS16221; XTEND-1: NCT04161495 ( https://clinicaltrials.gov/study/NCT04161495 ).Keywords
Funding Information
- Swedish Orphan Biovitrum
- Sanofi
This publication has 33 references indexed in Scilit:
- WFH Guidelines for the Management of Hemophilia, 3rd editionHaemophilia, 2020
- Young adult outcomes of childhood prophylaxis for severe hemophilia A: results of the Joint Outcome Continuation StudyBlood Advances, 2020
- BIVV001, a new class of factor VIII replacement for hemophilia A that is independent of von Willebrand factor in primates and miceBlood, 2020
- Multiyear Follow-up of AAV5-hFVIII-SQ Gene Therapy for Hemophilia ANew England Journal of Medicine, 2020
- Achieving the unimaginable: Health equity in haemophiliaHaemophilia, 2019
- The frequency of joint hemorrhages and procedures in nonsevere hemophilia A vs BBlood Advances, 2018
- Treatment adherence in hemophiliaPatient Preference and Adherence, 2017
- Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia ABlood, 2016
- Definitions in hemophilia: communication from the SSC of the ISTHJournal of Thrombosis and Haemostasis, 2014
- Clinical severity of haemophilia A: does the classification of the 1950s still stand?Haemophilia, 2011